Your browser doesn't support javascript.
loading
The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy.
Tkacz, Joseph; Garcia, Jacob; Gitlin, Mathew; McMorrow, Donna; Snyder, Sophie; Bonafede, Machaon; Chung, Karen C; Maziarz, Richard T.
Afiliación
  • Tkacz J; Life Sciences Division, IBM Watson Health, Bethesda, MD, USA.
  • Garcia J; †Global Drug Development, Juno Therapeutics, a Celgene company, Seattle, WA, USA.
  • Gitlin M; Strategic Health Economics, BluePath Solutions, Los Angeles, CA, USA.
  • McMorrow D; Life Sciences Division, IBM Watson Health, Bethesda, MD, USA.
  • Snyder S; Strategic Health Economics, BluePath Solutions, Los Angeles, CA, USA.
  • Bonafede M; Life Sciences Division, IBM Watson Health, Bethesda, MD, USA.
  • Chung KC; †Health Economics & Outcomes Research Group, Juno Therapeutics, a Celgene company, Seattle, WA, USA.
  • Maziarz RT; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Leuk Lymphoma ; 61(7): 1601-1609, 2020 07.
Article en En | MEDLINE | ID: mdl-32270727
We retrospectively analyzed treatment patterns and healthcare costs among patients diagnosed with diffuse large B-cell lymphoma (DLBCL) during each line of therapy (LOT) using data from the IBM® MarketScan® Commercial and Medicare Supplemental Databases from January 2011 to May 2017. Patients were included if they had a diagnosis of DLBCL, ≥12 months of disease-free continuous enrollment prediagnosis, and ≥1 month of postdiagnosis follow-up. Of 2066 eligible patients receiving first-line treatment, 17% (n = 340) received second-line treatment; of these, 23% (n = 77) received third-line treatment. Mean healthcare expenditures (treatment duration) for first, second, and third LOTs were $111,314 (124.5 days), $88,472 (80.8 days), and $103,365 (70.9 days), respectively. When adjusted to 30-day period costs, first, second, and third LOT healthcare expenditures increased to $26,825, $32,857, and $43,854, respectively. Patients with newly diagnosed and relapsed/refractory DLBCL incur a significant cost burden (for payers), and such costs increase as patients proceed through subsequent LOTs.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Costo de Enfermedad Tipo de estudio: Health_economic_evaluation / Observational_studies / Risk_factors_studies Límite: Aged / Humans País/Región como asunto: America do norte Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Costo de Enfermedad Tipo de estudio: Health_economic_evaluation / Observational_studies / Risk_factors_studies Límite: Aged / Humans País/Región como asunto: America do norte Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos